Ignite Creation Date:
2024-05-06 @ 2:05 AM
Last Modification Date:
2024-10-26 @ 11:14 AM
Study NCT ID:
NCT01968954
Status:
COMPLETED
Last Update Posted:
2017-05-17
First Post:
2013-10-21
Brief Title:
Randomized Clinical Trial Of Bococizumab PF-04950615 RN316 In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 3 Double-blindRandomized Placebo-controlledParallel-group Study To Assess The Efficacy Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SPIRE-HR
Brief Summary:
This study is a multicenter randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy safety and tolerability of Bococizumab PF-04950615RN316 to lower LDL-C
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SPIRE-HR | OTHER | Alias Study Number | None |
| 2013-002642-37 | EUDRACT_NUMBER | None | None |